Chemotherapy in stage I+II non-small cell lung cancer

Authors
Citation
D. Ukena, Chemotherapy in stage I+II non-small cell lung cancer, LUNG CANC, 33, 2001, pp. S25-S28
Citations number
12
Categorie Soggetti
Oncology
Journal title
LUNG CANCER
ISSN journal
01695002 → ACNP
Volume
33
Year of publication
2001
Supplement
1
Pages
S25 - S28
Database
ISI
SICI code
0169-5002(200109)33:<S25:CISINC>2.0.ZU;2-B
Abstract
Although surgical resection offers the best chance for long-term survival f or patients with non-small cell lung cancer (NSCLC), the limited number of resectable patients and the presence of micrometastatic disease is limiting the effectiveness of this modality as sole treatment. Results of randomize d trials demonstrated a survival benefit for preoperative (neoadjuvant) cis platin-based chemotherapy in patients with stage IIIA NSCLC compared to sur gery alone. In stage I + II NSCLC preoperative chemotherapy, although still experimental, clearly offers encouraging results. However, there is no evi dence of its superiority over adjuvant chemotherapy. Moreover, for adjuvant therapy a benefit has not been established yet. Possibly current ongoing o r recently finished trials may change the recommendations on adjuvant or ne oadjuvant therapy for completely resected or resectable early disease in th e future. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.